People with Type 2 diabetes who took the antidiabetes drug glitazone to decrease blood glucose levels and preserve the pancreas’ ability to produce insulin also had a reduced risk of developing Parkinson’s disease. Over a 10-year period, those who took glitazone had a 35% lower risk of developing Parkinson’s disease. Parkinson’s disease is a neurodegenerative disorder that affects about 2% of people age 65 and older. The prevalence increases with age. These findings were reported in “Glitazone Use Associated With Reduced Risk Of Parkinson's Disease” by Brage Brakedal, BA, M.D.; Irene Flønes, M . . .